Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Starter concentration
Conclusion Key Takeaways The evidence supporting tirzepatide as a dual GIP/GLP-1 receptor agonist demonstrates that this approach can achieve superior metabolic outcomes compared to single-pathway therapies
Standard protocols are once daily, typically at bedtime on an empty stomach (at least two hours after the last meal), to align with the natural overnight growth hormone pulse window
Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Fras JP, et al
US$ 21.34
US$ 26.83
US$ 20.74
